Palmoplantar Keratoderma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc.

Palmoplantar Keratoderma Pipeline constitutes 3+ key companies continuously working towards developing 3+ Palmoplantar Keratoderma treatment therapies, analyzes DelveInsight.

Palmoplantar Keratoderma Overview:

**Palmoplantar keratoderma (PPK)** refers to a group of skin disorders characterized by **thickened skin** on the **palms** and **soles**. It can be **acquired** (more common) due to health or environmental factors or **inherited** through genetic mutations affecting **keratin**, a key skin protein.

Symptoms of PPK include **widespread skin thickening (keratosis)** on the palms and soles, often with a **red band** at the edges. Additional keratotic lesions may develop on the **backs of the hands, feet, knees, and elbows**. Other common signs include **excessive sweating** and **thickened nails**.

Treatment typically involves **topical keratolytics**, such as **salicylic acid** and **benzoic acid compounds**, to help reduce skin thickening.

Request for a detailed insights report on Palmoplantar Keratoderma pipeline insights @ https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Palmoplantar Keratoderma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Palmoplantar Keratoderma Therapeutics Market.

Key Takeaways from the Palmoplantar Keratoderma Pipeline Report

DelveInsight's Palmoplantar Keratoderma pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Palmoplantar Keratoderma treatment.
Key Palmoplantar Keratoderma companies such as Sol-Gel Technologies Ltd., Krystal Biotech Inc., and others are evaluating new drugs for Palmoplantar Keratoderma to improve the treatment landscape.
Promising Palmoplantar Keratoderma pipeline therapies in various stages of development include SGT-210, and others.

Recent breakthroughs in the Palmoplantar Keratoderma Pipeline Segment:

A Phase 1b clinical study evaluated KM-001, a novel TRPV3 inhibitor, in patients with PPK, including Pachyonychia Congenita (PC) and Punctate Palmoplantar Keratoderma type 1 (PPPK1). The study demonstrated safety and preliminary efficacy, with 86% of participants in Israel and 88% in the UK showing improvement in at least one parameter, such as disease severity, pain, or itch. Notably, 47% of all patients improved in at least two parameters, and six out of ten PC patients reported pain reduction.
In 2024, Sol-Gel Technologies initiated a Phase 1 proof-of-concept study for SGT-210, targeting PPK. This study aims to assess the safety and efficacy of this novel therapeutic agent, marking a significant step in PPK treatment development.
A Phase 2 clinical trial is currently recruiting to evaluate the safety and efficacy of Tapinarof, a naturally occurring compound previously used for psoriasis, in adults with PPK. This study represents an effort to repurpose existing dermatological treatments for PPK management.
In August 2024, the European Medicines Agency (EMA) granted orphan designation to a novel compound, identified as (R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone, for the treatment of punctate palmoplantar keratoderma. This designation facilitates the development of treatments for rare diseases like PPK.

Palmoplantar Keratoderma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Palmoplantar Keratoderma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Palmoplantar Keratoderma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Palmoplantar Keratoderma market.

Download our free sample page report on Palmoplantar Keratoderma pipeline insights @ https://www.delveinsight.com/sample-request/palmoplantar-keratoderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Palmoplantar Keratoderma Emerging Drugs

SGT-210: Sol-Gel technologies Ltd.

Palmoplantar Keratoderma Companies

Approximately three or more key companies are actively developing therapies for Palmoplantar Keratoderma. Among them, Sol-Gel Technologies Ltd. has the most advanced drug candidate currently in Phase I clinical trials.

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Palmoplantar Keratoderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Palmoplantar Keratoderma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Palmoplantar Keratoderma Therapies and Key Companies: Palmoplantar Keratoderma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Palmoplantar Keratoderma Pipeline Therapeutic Assessment
• Palmoplantar Keratoderma Assessment by Product Type
• Palmoplantar Keratoderma By Stage
• Palmoplantar Keratoderma Assessment by Route of Administration
• Palmoplantar Keratoderma Assessment by Molecule Type

Download Palmoplantar Keratoderma Sample report to know in detail about the Palmoplantar Keratoderma treatment market @ Palmoplantar Keratoderma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/palmoplantar-keratoderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Palmoplantar Keratoderma Current Treatment Patterns
4. Palmoplantar Keratoderma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Palmoplantar Keratoderma Late-Stage Products (Phase-III)
7. Palmoplantar Keratoderma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Palmoplantar Keratoderma Discontinued Products
13. Palmoplantar Keratoderma Product Profiles
14. Palmoplantar Keratoderma Key Companies
15. Palmoplantar Keratoderma Key Products
16. Dormant and Discontinued Products
17. Palmoplantar Keratoderma Unmet Needs
18. Palmoplantar Keratoderma Future Perspectives
19. Palmoplantar Keratoderma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Palmoplantar Keratoderma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.